您当前所在的位置:首页 > 产品中心 > 产品信息
Ridogrel_分子结构_CAS_110140-89-1)
点击图片或这里关闭

Ridogrel

产品号 DB01207 公司名称 DrugBank
CAS号 110140-89-1 公司网站 http://www.ualberta.ca/
分子式 C18H17F3N2O3 电 话 (780) 492-3111
分子量 366.3343896 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 1077

产品价格信息

请登录

产品别名

标题
Ridogrel
IUPAC标准名
5-{[(E)-{pyridin-3-yl[3-(trifluoromethyl)phenyl]methylidene}amino]oxy}pentanoic acid
IUPAC传统名
ridogrelum
别名
Ridogrelum [INN-Latin]

产品登记号

PubChem SID 46506774
PubChem CID 5362391
CAS号 110140-89-1

产品性质

疏水性(logP) 4.3

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction. However, there currently are no clinical indications for preferential use of ridogrel over aspirin.
Indication Used as an adjunctive therapy to induce thrombolysis in patients suffering acute myocardial infarction.
Pharmacology Ridogrel, a combined thromboxane synthase inhibitor and receptor antagonist, is used with streptokinase as an adjunctive therapy to reduce the formation and size of blood clots. Blood clots can cause ischemic cardiac events (heart attacks). Ridogrel has the dual property of inhibiting the synthesis of thromboxane and blocking the receptors of thromboxane/prostaglandin/endoperoxides. It has been shown to accelerate the speed of recanalization and to delay or prevent reocclusion during systemic thrombolysis with tissue plasminogen activator (streptokinase). Ridogrel is a more potent antiplatelet agent than aspirin and might offer an advantage over aspirin as an adjunct to thrombolysis in patients suffering from acute myocardial infarction. While aspirin inhibits cyclooxygenase, the enzyme responsible for producing thromboxane, ridogrel inhibits thromboxane synthesis directly. A recent comparison between aspirin and ridogrel in as adjunct to thrombolysis in patients with acute myocardial infarction demonstrated that ridogrel is not superior to aspirin in enhancing the fibrinolytic efficacy of streptokinase but might be more effective in preventing new ischemic events. Clinical experience with this drug is still relatively limited.
Affected Organisms
Humans and other mammals
Absorption Rapidly absorbed after oral administration (30-60 min)
Protein Binding Approximately 60% bound to plasma proteins

参考文献